On Feb. 19, 2021, Johnson & Johnson announced that Janssen-Cilag had submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered included interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. The Companyﾒs rolling submission of clinical data to WHO was completed.